NCT01421901

Brief Summary

The acute appendicitis (AA) is a very common disease with a life time risk 7-8% and the highest incidence in the second decades . The aetiology of AA is still poor understood: the commonest hypothesis refers to appendix obstruction followed by impairment of wall appendix barrier and thus wall perforation and/or abscess formation1. However some studies suggest that no-complicate and complicate appendicitis are different entities allowing a different treatment. The study aims to test the no inferiority in terms of efficacy of antibiotic treatment compared to surgery in a population with high probability to suffer of 1st episode of AA.The study aims to test the no inferiority in terms of efficacy of antibiotic treatment compared to surgery in a population with high probability to suffer of 1st episode of AA.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
218

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Aug 2011

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

August 4, 2011

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 23, 2011

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

June 17, 2014

Status Verified

June 1, 2014

Enrollment Period

3.3 years

First QC Date

August 4, 2011

Last Update Submit

June 16, 2014

Conditions

Keywords

Acute appendicitisSurgeryAntibioticscomparison surgery and antibioticsresolutions of symptoms

Outcome Measures

Primary Outcomes (1)

  • the rate of patients free of symptoms into 2 weeks (from operation in the surgery group or from the third Ertapenem administration in the antibiotics group) with no pain, no fever, WBC ≤ 10000, CRP ≤ 1

    2 weeks

Secondary Outcomes (1)

  • Secondary outcomes will be considered major complications occurring after 2 weeks and into 1 year. Phone consultation will be performed at 1 year

    2 weeks- One year

Study Arms (2)

Ertapenem

EXPERIMENTAL
Drug: Ertapenem

appendectomy

ACTIVE COMPARATOR

Appendectomy is compared to Ertapenem

Procedure: appendectomy

Interventions

Ertapenem i.v,m 1g, once a day, 3 days

Ertapenem
appendectomyPROCEDURE
appendectomy

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients between 18 and 65 years old
  • first episode of suspected AA diagnosed by Andersson's score or combination with abdominal ultrasound

You may not qualify if:

  • patients with any potential immunodeficiency status
  • assumption of antibiotics for different infectious disease or surgery in the last 30 days
  • allergy to antibiotics established in the study protocol
  • no acceptance of study protocol
  • pregnancy or delivery in the last 6 months
  • ASA IV or V, no Italian or English fluently speakers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

1St General Surgery Unit Papa Giovanni XXIII Hospital Bergamo

Bergamo, 24127, Italy

RECRUITING

MeSH Terms

Conditions

Appendicitis

Interventions

ErtapenemAppendectomy

Condition Hierarchy (Ancestors)

Intraabdominal InfectionsInfectionsGastroenteritisGastrointestinal DiseasesDigestive System DiseasesCecal DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Carbapenemsbeta-LactamsLactamsAmidesOrganic ChemicalsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDigestive System Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Luca Ansaloni

    Papa Giovanni XXIII Hospital Bergamo

    STUDY DIRECTOR
  • Michele Pisano

    Papa Giovanni XXIII Hospital Bergamo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michele Pisano, Principal investigator

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

August 4, 2011

First Posted

August 23, 2011

Study Start

August 1, 2011

Primary Completion

December 1, 2014

Study Completion

June 1, 2015

Last Updated

June 17, 2014

Record last verified: 2014-06

Locations